Table 1 Clinical and MRI features of patients in the training and validation group

HLN

NHLN

31

31

/

MHLN

21

21

Gender

male/female

12/40

19/33

0.133

Age

52.85 ± 9.19

56.69 ± 10.86

0.054

BMI

24.37 ± 3.04

23.71 ± 3.11

0.273

Primary location

Right−/left-side

11/41

11/41

/

Differentiation

Low to moderate/High

51/1

51/1

/

T stage of primary tumor

T1 + 2/T3 + 4

5/47

2/50

0.437

N stage of primary tumor

N0/N+

4/48

10/42

0.149

Gene

RAS-wild

32

32

0.650

RAS-mutation

19

17

Braf-mutation

1

3

Simultaneous liver metastases

No/Yes

13/39

10/42

0.478

Distribution

Solitary/Bilateral

15/37

23/29

0.103

Number of CRLM

≤5/>5

24/28

38/14

0.027*

Size (mm)

43.17 ± 28.90

37.46 ± 20.87

0.420

RECIST evaluation

Response/Non- Response

31/21

28/24

0.553

pre-CEA

≤5/>5 ng/ml

8/37

12/37

0.368

pre-CA199

≤40/>40 U/ml

16/31

17/30

0.829

post-CEA

≤5/>5 ng/ml

19/33

29/23

0.049*

post-CA199

≤40/>40 U/ml

29/29

29/19

/

Shape of HLN

Regular/Irregular

43/9

40/12

0.464

Signal intensity of HLN

Homogeneous/Hetergeneous

41/11

37/15

0.365

Short axis of HLN at baseline

mm

8.54 ± 3.63

8.63 ± 4.44

0.904

Long axis of HLN at baseline

mm

16.17 ± 6.77

15.17 ± 6.48

0.443

Pre-ADC_mean

mm²/s

1513.08 ± 311.09

1590.10 ± 333.12

0.226

Pre-ADC_min

mm²/s

1107.94 ± 300.83

1169.13 ± 341.12

0.334

Pre-rADC_-lm

1.21 ± 0.29

1.38 ± 0.32

0.006

Pre-rADC_-sp

1.82 ± 0.34

1.90 ± 0.44

0.330

Pre-rADC_-m

1.11 ± 0.24

1.18 ± 0.24

0.182

Short axis of HLN at endpoint

mm

8.15 ± 3.10

7.81 ± 3.30

0.583

Long axis of HLN at endpoint

mm

15.58 ± 6.59

14.42 ± 6.32

0.364

Post-ADC_mean

mm²/s

1563.46 ± 272.00

1575.88 ± 374.27

0.847

Post-ADC_min

mm²/s

1166.77 ± 289.29

1156.79 ± 360.96

0.977

Post -rADC_-lm

1.25 ± 0.32

1.26 ± 0.38

0.869

Post -rADC_-sp

1.93 ± 0.45

1.86 ± 0.40

0.388

Post-rADC_-m

1.11 ± 0.22

1.16 ± 0.28

0.380

ΔADC

6.04 ± 24.63

3.39 ± 25.67

0.435